Showing results (141-150 of 165) with videos related to
Sort By:
Pageof 17
Leukemia|March 9, 2018
Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNetTiziano Barbui, Ayalew Tefferi, Alessandro M Vannucchi, et al.Hemasphere|October 30, 2023
Patient-reported Outcomes and Quality of Life in Anemic and Symptomatic Patients With Myelofibrosis: Results From the MOMENTUM StudyRuben A Mesa, Claire Harrison, Jeanne M Palmer, et al.Molecular Systems Biology|May 27, 2025
Unique trajectory of gene family evolution from genomic analysis of nearly all known species in an ancient yeast lineageBo Feng, Yonglin Li, Biyang Xu, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 2, 2026
Selinexor Plus Ruxolitinib in JAK Inhibitor-Naïve Myelofibrosis: Phase 3 SENTRY TrialPrithviraj Bose, Haris Ali, Haifa Kathrin Al-Ali, et al.Leukemia Research|May 20, 2014
Circulating YKL-40 in patients with essential thrombocythemia and polycythemia vera treated with the novel histone deacetylase inhibitor vorinostatChristen Lykkegaard Andersen, Mads Emil Bjørn, Mary Frances McMullin, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 7, 2023
MANIFEST: Pelabresib in Combination With Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve MyelofibrosisJohn Mascarenhas, Marina Kremyanskaya, Andrea Patriarca, et al.The Lancet. Haematology|December 7, 2023
Indication and management of allogeneic haematopoietic stem-cell transplantation in myelofibrosis: updated recommendations by the EBMT/ELN International Working GroupNicolaus Kröger, Andrea Bacigalupo, Tiziano Barbui, et al.Haematologica|May 14, 2016
Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutationAlberto Alvarez-Larrán, Arturo Pereira, Paola Guglielmelli, et al.The Lancet. Haematology|December 9, 2022
Splenomegaly in patients with primary or secondary myelofibrosis who are candidates for allogeneic hematopoietic cell transplantation: a Position Paper on behalf of the Chronic Malignancies Working Party of the EBMTNicola Polverelli, Juan Carlos Hernández-Boluda, Tomasz Czerw, et al.Blood|November 14, 2023
Outcomes and characteristics of nonmelanoma skin cancers in patients with myeloproliferative neoplasms on ruxolitinibAlex Rampotas, Luke Carter-Brzezinski, Tim C P Somervaille, et al.Pageof 17